These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 27834141)
1. In Vitro Exploration of the Anti-HCV Potential of the Synthetic Spacer Peptides Derived from Human, Bovine, and Camel Lactoferrins. Albar AH; El-Fakharany EM; Almehdar HA; Uversky VN; Redwan EM Protein Pept Lett; 2017; 24(10):909-921. PubMed ID: 27834141 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study. El-Fakharany EM; Sánchez L; Al-Mehdar HA; Redwan EM Virol J; 2013 Jun; 10():199. PubMed ID: 23782993 [TBL] [Abstract][Full Text] [Related]
3. Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus. Redwan EM; El-Fakharany EM; Uversky VN; Linjawi MH BMC Complement Altern Med; 2014 Jul; 14():219. PubMed ID: 24993815 [TBL] [Abstract][Full Text] [Related]
4. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. Redwan el-RM; Tabll A J Immunoassay Immunochem; 2007; 28(3):267-77. PubMed ID: 17613672 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells. Liao Y; El-Fakkarany E; Lönnerdal B; Redwan EM J Med Microbiol; 2012 Mar; 61(Pt 3):375-383. PubMed ID: 22052996 [TBL] [Abstract][Full Text] [Related]
6. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Ikeda M; Nozaki A; Sugiyama K; Tanaka T; Naganuma A; Tanaka K; Sekihara H; Shimotohno K; Saito M; Kato N Virus Res; 2000 Jan; 66(1):51-63. PubMed ID: 10653917 [TBL] [Abstract][Full Text] [Related]
7. Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma. El-Fakharany EM; Abedelbaky N; Haroun BM; Sánchez L; Redwan NA; Redwan EM Virol J; 2012 Sep; 9():201. PubMed ID: 22978304 [TBL] [Abstract][Full Text] [Related]
8. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Abe K; Nozaki A; Tamura K; Ikeda M; Naka K; Dansako H; Hoshino HO; Tanaka K; Kato N Microbiol Immunol; 2007; 51(1):117-25. PubMed ID: 17237607 [TBL] [Abstract][Full Text] [Related]
9. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Ikeda M; Sugiyama K; Tanaka T; Tanaka K; Sekihara H; Shimotohno K; Kato N Biochem Biophys Res Commun; 1998 Apr; 245(2):549-53. PubMed ID: 9571193 [TBL] [Abstract][Full Text] [Related]
10. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204 [TBL] [Abstract][Full Text] [Related]
11. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. Nozaki A; Ikeda M; Naganuma A; Nakamura T; Inudoh M; Tanaka K; Kato N J Biol Chem; 2003 Mar; 278(12):10162-73. PubMed ID: 12522210 [TBL] [Abstract][Full Text] [Related]
12. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803 [TBL] [Abstract][Full Text] [Related]
14. Screening and rational design of hepatitis C virus entry inhibitory peptides derived from GB virus A NS5A. Liu X; Huang Y; Cheng M; Pan L; Si Y; Li G; Niu Y; Zhao L; Zhao J; Li X; Chen Y; Yang W J Virol; 2013 Feb; 87(3):1649-57. PubMed ID: 23175359 [TBL] [Abstract][Full Text] [Related]
15. Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens. Zarzosa-Moreno D; Avalos-Gómez C; Ramírez-Texcalco LS; Torres-López E; Ramírez-Mondragón R; Hernández-Ramírez JO; Serrano-Luna J; de la Garza M Molecules; 2020 Dec; 25(24):. PubMed ID: 33302377 [TBL] [Abstract][Full Text] [Related]
16. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825 [TBL] [Abstract][Full Text] [Related]
17. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions. Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830 [TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. Scala MC; Sala M; Pietrantoni A; Spensiero A; Di Micco S; Agamennone M; Bertamino A; Novellino E; Bifulco G; Gomez-Monterrey IM; Superti F; Campiglia P Sci Rep; 2017 Sep; 7(1):10593. PubMed ID: 28878220 [TBL] [Abstract][Full Text] [Related]
19. A reliable internally controlled RT-nested PCR method for the detection of hepatitis C virus RNA. Nozaki A; Naganuma A; Nakamura T; Tanaka K; Sekihara H; Kato N Acta Med Okayama; 2000 Dec; 54(6):253-7. PubMed ID: 11132918 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide. Florian PE; Macovei A; Lazar C; Milac AL; Sokolowska I; Darie CC; Evans RW; Roseanu A; Branza-Nichita N J Med Virol; 2013 May; 85(5):780-8. PubMed ID: 23508903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]